- $1.22bn
- $1.27bn
- $606.88m
Brief: OPKO Health Q2 Net Income USD -148.4 Million
Opko Health Inc Expected To Post A Loss Of 11 Cents A Share: Earnings Preview
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Opko Health Inc Reports Results For The Quarter Ended March 31: Earnings Summary
Brief: OPKO Health Q1 Net Income USD -67.6 Million
Opko Health Inc Expected To Post A Loss Of 7 Cents A Share: Earnings Preview
Brief: NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program
Brief: Opko Health Announces $100 Million Increase To Its Existing Share Repurchase Program
OPKO and Entera partner to develop obesity pill
Brief: Labcorp Announces Acquisition Of Select Assets Of Bioreference Health's Innovative Oncology And Related Clinical Testing Services Businesses
Opko Health Inc Reports Results For The Quarter Ended December 31: Earnings Summary
Brief: OPKO Health Q4 Net Income USD 14 Million
Brief: OPKO Health’S Modex Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study In Collaboration With Merck
Factbox: Weight-loss drug developers line up to tap market worth $150 billion
Opko Health Inc Reports Results For The Quarter Ended In September 30: Earnings Summary
Brief: OPKO Health Q3 Net Income USD 24.9 Million
Brief: Nextplat Four-Year Extension Of Opko Healthcare E-Commerce Program In China
Brief: Modex Therapeutics Secures $35 mln Barda Supplement To Develop Covid Multispecific Antibodies
Brief: Entera Bio And Opko Health Provide Update On Pk/Pd Results Of Oral Oxyntomodulin (Glp-1/Glucagon) Peptide Tablet Candidate For Obesity And Metabolic Disorders